Compatibility in cancer refers to how closely a donor’s tissue markers match a patient’s, especially in hematopoietic stem cell transplantation, where human leukocyte antigen (HLA) matching reduces the risk of graft rejection and graft-versus-host disease (GVHD). This relationship between donor and patient influences transplant success, treatment intensity, and long-term recovery. The following explains key concepts, testing methods, donor sources, and practical implications of compatibility in cancer care.
What Compatibility Means in Cancer Treatment
Compatibility centers on immune system markers that indicate how foreign a donor’s cells will appear to the recipient’s immune system. The closer the match, the lower the chance of serious complications such as rejection or GVHD, in which donor immune cells attack the recipient’s tissues. Clinicians evaluate multiple loci, often focusing on HLA-A, HLA-B, HLA-DR, and sometimes additional markers. While compatibility is frequently discussed in the context of bone marrow or stem cell transplantation, it also matters for some immunotherapies and when donor lymphocytes are transferred to fight cancer (donor lymphocyte infusion).
Key Testing and Match Grading
High-Resolution HLA Typing
High-resolution DNA typing determines HLA alleles at the locus level, replacing older serologic methods. Results are reported as allele-specific codes (e.g., HLA-A*02:01), allowing precise comparison between donor and recipient. Match quality is graded by the number of alleles shared: ideally, 8 to 10 out of 10 alleles match across major loci in unrelated donor transplants, while related sibling matches often provide 10 out of 10 matches when available.
What Is Considered a Good Match
- Identical twins: 10 out of 10 alleles matched (perfect match)
- Matched related donor (sibling): typically 10 out of 10 alleles matched
- Unrelated donor on registry: 8 to 10 out of 10 alleles matched preferred
- Haploidentical (half-match): 5 out of 10 alleles matched, used when no better option exists
Higher match counts generally associate with lower rates of GVHD and transplant-related mortality, though other factors—disease stage, age, and prior therapies—also influence outcomes.
| Match Type | Verified Detail | Source Type |
|---|---|---|
| Identical twin / syngeneic | 10/10 HLA alleles matched | Clinical consensus |
| Matched sibling | Often 10/10 HLA alleles matched | Clinical consensus |
| Unrelated donor (Bone Marrow Donor Program) | 8–10/10 HLA alleles matched preferred | Transplant guidelines |
| Haploidentical relative | 5/10 HLA alleles matched | Transplant guidelines |
Donor Sources and Compatibility Considerations
Three primary donor sources exist, each with distinct compatibility profiles:
- Related donors: siblings or family members who share inherited haplotypes; siblings have a 25% chance of being a full match.
- Unrelated donors: volunteers from national registries who undergo high-resolution typing; availability and match quality vary by ancestry due to population diversity in HLA alleles.
- Umbilical cord blood: units with lower cell doses may tolerate slightly less stringent HLA matching, useful when no adult donor is available; engraftment may be slower and GVHD risk context-dependent.
When a family member is a haploidentical match (parent, child, or half-sibling), advanced T-cell separations and post-transplant cyclophosphamide can make these transplants feasible, expanding access when matched donors are absent.
How Compatibility Influences Treatment Decisions
Oncology teams weigh compatibility against urgency, disease risk, and patient age. For acute leukemias and high-risk lymphomas, a well-matched unrelated donor or haploidentical transplant may be pursued with conditioning regimens tailored to reduce rejection and GVHD. Older adults or those with significant comorbidities sometimes receive reduced-intensity conditioning to tolerate mismatched grafts. Clinical trials may explore mismatched unrelated donors or alternative stem cell sources when standard options are limited.
Practical Outcomes and Limitations
Even with a high-level match, outcomes vary based on disease characteristics, prior treatments, and post-transplant care. Graft failure, infections, and chronic GVHD remain risks irrespective of matching. Compatibility testing cannot predict every complication, and two patients with identical HLA matches may experience different recoveries. Therefore, compatibility informs—but does not guarantee—transplant success.
Conclusion and Takeaways
- Compatibility is measured primarily by HLA marker matching, ideally 8–10/10 alleles for unrelated donors.
- Related siblings are most likely to provide a full match; registries and cord blood banks expand unrelated options.
- Match quality influences transplant strategy, but disease urgency, patient fitness, and available therapies also guide decisions.
- Haploidentical transplants, while less matched, are increasingly viable with modern supportive care and graft manipulation techniques.
- Ongoing registries and research aim to improve matching, reduce disparities, and extend access across diverse populations.
Patients and caregivers should discuss specific HLA typing, donor availability, and conditioning options with their transplant team to understand how compatibility fits into their overall cancer care plan.